Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9210565 | 0.85 | ALDH1A1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL10284153 | 0.82 | ALDH1A1 (0.78) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL5503439 | 0.81 | ALDH1A1 (0.81) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL5537126 | 0.81 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL10915913 | 0.81 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL12124412 | 0.81 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL3049673 | 0.81 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL20783160 | 0.80 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL18997054 | 0.80 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL26614510 | 0.80 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2024-08-06 | — | — | US | disclosed |
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | US | disclosed |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-10 | — | — | US | disclosed |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-11655221-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-20230116721-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-04-13 | — | — | US | disclosed |
| US-20230115170-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-04-13 | — | — | US | disclosed |
| US-20230069044-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-03-02 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100329978-A1 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS | UNIVERSITY OF MISSISSIPPI (US) | 2010-12-30 | — | — | US | disclosed |
| US-7279444-B2 | Substituted benzoylpyrazoles | BAYER CROPSCIENCE GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7279444-B2 | Substituted benzoylpyrazoles | BAYER CROPSCIENCE GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
| US-20100329978-A1 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS | SIGMAR1, OPRL1, CNR1 | MAPK1 2095/4885TSHR 45/4885HPGD 1985/4885 |
| US-20230115170-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | MAPK1 2175/4885TSHR 4207/4885HPGD 669/4885 |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | MAPK1 1147/4885TSHR 436/4885HPGD 772/4885 |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
| US-20230069044-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
| US-11655221-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
| US-11655223-B2 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPP3 | MAPK1 2166/4885TSHR 4220/4885HPGD 710/4885 |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | MAPK1 2175/4885TSHR 4207/4885HPGD 669/4885 |
| US-20230116721-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | MAPK1 2175/4885TSHR 4207/4885HPGD 669/4885 |
| US-11680049-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | MAPK1 2235/4885TSHR 4180/4885HPGD 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.